2025-06-20 2025-06-20 , online online, 690 € zzgl. MwSt. Marianne Lambertson https://www.forum-institut.de/seminar/25102203-pharma-pricing-under-pressure-u-s-reforms-and-potential-implications-for-the-eu-industr/referenten/25/25_10/25102203-us-price-regulation_lambertson-marianne.jpg Pharma Pricing Under Pressure: U.S. Reforms and Potential Implications for the EU Industry

Explore how recent U.S. pharmaceutical pricing reforms may impact the European pharma sector. This online seminar provides a transatlantic perspective on policy trends, trade risks, and pricing dynamics.

Topics
  • Comparative overview of pharmaceutical pricing between the U.S. and Europe-
  • CMS/Medicare pricing negotiations and potential implications of the proposed Most Favored Nation (MFN) pricing model
  • Potential U.S. reform initiatives: price referencing and proposed tariffs on pharmaceuticals
  • Potential strategic impacts on the EU pharmaceutical industry, payers, and patients


Who should attend
This seminar is designed for professionals and decision-makers from the pharmaceutical industry across Germany and Europe, particularly those working in the areas of:
  • Market Access
  • Pricing & Reimbursement
  • Health Economics
  • International Strategy and Business Development
Aims and objectives
This seminar offers an overview of current transatlantic developments in pharmaceutical pricing. Participants will gain insight into key differences between the U.S. and European pricing structures, with a particular focus on U.S. reforms and their global repercussions. Special attention will be paid to CMS/Medicare negotiation mechanisms, the potential implications of the proposed Most Favored Nation (MFN) pricing model and the emerging threat of U.S. tariffs on pharmaceuticals.

The seminar concludes with an outlook on potential implications for the European pharmaceutical landscape, including potential consequences for manufacturers, payers, and patients.
Your benefit

  • Gain early insight into policy shifts that could reshape global pharmaceutical markets.
  • Understand the legal and commercial risks posed by U.S. price control initiatives and trade measures.
  • Stay informed on how U.S. price negotiations and tariff policies may influence EU pricing strategies and export compliance.

Pharma Pricing Under Pressure: U.S. Reforms and Potential Implications for the EU Industry

Pharma Pricing Under Pressure: U.S. Reforms and Potential Implications for the EU Industry

Benefits
  • Stay ahead of policy shifts with expert insights
  • Understand the global impact of U.S. pharma pricing reforms
  • Officially certified according to ISO 9001 and ISO 21001

Webcode 25102203

Jetzt buchen

JETZT Buchen

Referenten


Alles auf einen Blick

Termin

16/10/2025

16/10/2025

Zeitraum

1:00 pm - 4:30 pm online seminar
You may dial in 30 minutes in advance

1:00 pm - 4:30 pm online seminar
You may dial in 30 minutes in advance
Veranstaltungsort

online

online

Gebühr
Your contact

Leila Dörfler
Team Leader Pharma & Healthcare

+49 6221 500-695
l.doerfler@forum-institut.de

Details

Explore how recent U.S. pharmaceutical pricing reforms may impact the European pharma sector. This online seminar provides a transatlantic perspective on policy trends, trade risks, and pricing dynamics.

Topics

  • Comparative overview of pharmaceutical pricing between the U.S. and Europe-
  • CMS/Medicare pricing negotiations and potential implications of the proposed Most Favored Nation (MFN) pricing model
  • Potential U.S. reform initiatives: price referencing and proposed tariffs on pharmaceuticals
  • Potential strategic impacts on the EU pharmaceutical industry, payers, and patients


Who should attend
This seminar is designed for professionals and decision-makers from the pharmaceutical industry across Germany and Europe, particularly those working in the areas of:
  • Market Access
  • Pricing & Reimbursement
  • Health Economics
  • International Strategy and Business Development

Aims and objectives

This seminar offers an overview of current transatlantic developments in pharmaceutical pricing. Participants will gain insight into key differences between the U.S. and European pricing structures, with a particular focus on U.S. reforms and their global repercussions. Special attention will be paid to CMS/Medicare negotiation mechanisms, the potential implications of the proposed Most Favored Nation (MFN) pricing model and the emerging threat of U.S. tariffs on pharmaceuticals.

The seminar concludes with an outlook on potential implications for the European pharmaceutical landscape, including potential consequences for manufacturers, payers, and patients.

Your benefit

  • Gain early insight into policy shifts that could reshape global pharmaceutical markets.
  • Understand the legal and commercial risks posed by U.S. price control initiatives and trade measures.
  • Stay informed on how U.S. price negotiations and tariff policies may influence EU pricing strategies and export compliance.

Detailed programme

1:00 pm - 4:30 pm online seminar
You may dial in 30 minutes in advance

13:00 Welcome and Introduction


13:15

Marianne Lambertson, Jo Wallis

Price Discrepancies in Pharmaceuticals: A Transatlantic Comparison
  • Overview of current price differentials between the U.S. and Europe
  • Key structural causes: reimbursement systems, negotiation powers, R&D costs

13:45

Marianne Lambertson, Jo Wallis

CMS/Medicare Price Negotiations and Their Global Relevance
  • The evolving role of CMS in setting price targets under the Trump administration
  • Most Favored Nation (MFN) pricing strategy: concept, scope, and execution
  • Strategic implications for European pharmaceutical companies exporting to the U.S.

14:15 Short Break


14:30

Marianne Lambertson, Jo Wallis

Emerging US Policy Risks: Tariffs and International Price Referencing
  • Overview of proposed US tariffs on pharmaceutical products
  • The role of international price referencing in U.S. reform efforts
  • Risks for EU-based exporters and concerns from the industry
  • Regulatory uncertainty and compliance challenges

15:30

Christian Thams

European Consequences: Impact on Industry, Payers and Patients?

16:30 End of the seminar


Ihr Nutzen

Technical requirements

You need a reliable Internet connection to take part in our online events. To have the best possible learning experience, we recommend that you use the latest version of the Microsoft Edge or Google Chrome browsers. You will need a headset, loudspeaker or telephone to play the audio. Further information is available here. Please check beforehand that your microphone or headset and camera are working properly. Do not access our services from a VPN since there are issues with the audio over such connections.

We have integrated Zoom video conferencing software into our Learning Space for our online training courses. If you are not authorised to use Zoom, please get in touch with us so we can make alternative arrangements for you to take part in our online training.

This distinguishes our events

of 5 stars of all ratings from 2024

of 5 stars on Trustpilot = good

Recommendations

Strategic Market Access in Europe: From HTA to Pricing Negotiations

This online seminar provides a comprehensive introduction to drug market access and pricing strategies in five key Europ...

09. - 10.12.2025 in
Details

Patient Involvement in HTA

This course offers a deep dive into patient involvement in HTA processes across Europe, with a focus on the UK and Germa...

10.09.2025 in
Details

Global Value Demonstration, Market Access & Pricing

You will gain actionable insights into global market access strategies, payer evidence requirements, and health economic...

29.09.2025 in
Details

Leveraging AI in Evidence Generation and Market Access

Using AI for clinical data evaluation, systematic literature reviews, dossier writing, and PICO simulations - the essent...

10.07.2025 in
Details

AMNOG and the EU HTA - Insights into the German Market

This seminar will focus on AMNOG and JCA dossier preparation as well as the German AMNOG procedure in comparison with th...

23.09.2025 in
Details

Go forward

Our international course portfolio

Are you interested in our international continuous education programme? We provide a variety of specialised courses.

Details
Our international course portfolio
List of abbreviations pharma & healthcare

Many abbreviations are used in pharma & healthcare. Download the list of the most important ones.

Details
Abbreviations, Glossary
We guarantee the highest quality

We are now officially certified to ISO 9001 and ISO 21001 standard.

Details
We guarantee the highest quality